21807_Hyperkalemia and Heart Failure

In this program, Dr. Paul Hauptman and Dr. Javed Butler will 1) describe the relationship between RAAS inhibitors, hyperkalemia, and cardiovascular risk, 2) identify goals and treatments for acute, intermediate, and chronic management, and 3) discuss the clinical profi les of, and clinical settings for the use of, new potassium binders.

Hyperkalemia in heart failure (HF) patients is associated with serious clinical consequences, including emergency department visits, hospitalizations, progression of cardiac disease, and mortality. Causes of hyperkalemia are multifactorial, and signs/symptoms are usually mild
or absent. Even mild to moderate hyperkalemia has been associated with worse clinical outcomes. While inhibitors of the renin-angiotensin-aldosterone system (RAAS) are proven life-saving therapies in HF patients, they are associated with hyperkalemia. Although evidence indicates
the morbidity and mortality benefi t for remaining on these drugs, in clinical practice they are often discontinued, or their dosage reduced to suboptimal levels due to worsening renal function (WRF) and hyperkalemia, or the fear ofi nducing WRF and hyperkalemia. As a result, patients are placed at increased cardiovascular risk. There are different treatment strategies for acute, intermediate (subacute), and chronic hyperkalemia; new treatments are expanding the armamentarium of therapies available for management. In this program, Dr. Paul Hauptman and Dr. Javed Butler will 1) describe the relationship between RAAS inhibitors, hyperkalemia, and cardiovascular risk, 2) identify goals and treatments for acute, intermediate, and chronic management, and 3) discuss the clinical profi les of, and clinical settings for the use of, new potassium binders.

Login to your Account